Graviton, founded with a mission to develop innovative therapeutics for serious diseases, focuses on creating treatments for autoimmune disorders, cancer, genetic conditions, and fibrotic diseases. The company's flagship product, TDI01, is a highly selective and potent inhibitor of ROCK2, currently under study in the United States for the treatment of idiopathic pulmonary fibrosis (IPF). Graviton aims to advance this therapeutic into human clinical trials to address unmet medical needs.
Key figures affiliated with Graviton include leading scientists and industry experts dedicated to pioneering new treatment modalities. The company has garnered attention for its potential impact on treating IPF, a condition with limited therapeutic options. By advancing TDI01 and other novel therapeutics, Graviton is poised to make significant contributions to the field of biomedicine, potentially improving outcomes for patients with serious and life-threatening diseases.